Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 May 20:16:1604337.
doi: 10.3389/fimmu.2025.1604337. eCollection 2025.

Commentary: Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling

Giulia Valdiserra  1 , Clelia Di Salvo  1 , Matteo Fornai  1 , Luca Antonioli  1
Affiliations
Comment

Commentary: Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling

Giulia Valdiserra et al. Front Immunol. .
No abstract available

Keywords: CD64; IL-23; IL-23p19 subunit inhibitors; guselkumab; immune-mediated inflammatory diseases; pain.

PubMed Disclaimer

Conflict of interest statement

LA is scientific consultant for Eli Lilly and Johnson and Johnson. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
IL-23, through the JAK/STAT pathway, promotes the release of various cytokines, including IL-17A, IL-17F, IL-21, IL-22, CCL-20, IL-23, IL-8, INF-γ, TNF, IL-6, CCL-2, and GM-CSF. CD64 activation by immune complexes triggers the release of CCL-3, substance P (SP), CX3CL-1, TNF, IL-6, CCL-2, and GM-CSF. Anti-IL-23 antibodies, such as risankizumab, mirikizumab, and guselkumab, inhibit IL-23 signaling by targeting its p19 subunit. Additionally, guselkumab reduces CD64 expression, thereby weakening the downstream signaling associated with this protein.
See this image and copyright information in PMC

Comment on

  • Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling.
    Sachen KL, Hammaker D, Sarabia I, Stoveken B, Hartman J, Leppard KL, Manieri NA, Bao P, Greving C, Lacy ER, DuPrie M, Wertheimer J, Deming JD, Brown J, Hart A, Li HH, Freeman TC, Keyes B, Kohler K, White I, Karpowich N, Steele R, Elloso MM, Fakharzadeh S, Goyal K, Lavie F, Abreu MT, Allez M, Atreya R, Bissonnette R, Eyerich K, Krueger JG, McGonagle D, McInnes IB, Ritchlin C, Fourie AM. Sachen KL, et al. Front Immunol. 2025 Mar 12;16:1532852. doi: 10.3389/fimmu.2025.1532852. eCollection 2025. Front Immunol. 2025. PMID: 40145093 Free PMC article.

References

    1. Schett G, McInnes IB, Neurath MF. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N Engl J Med. (2021) 385:628–39. doi: 10.1056/NEJMra1909094 - DOI - PubMed
    1. Krueger JG, Eyerich K, Kuchroo VK, Ritchlin CT, Abreu MT, Elloso MM, et al. . IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. (2024) 15:1331217. doi: 10.3389/fimmu.2024.1331217 - DOI - PMC - PubMed
    1. Ohara D, Takeuchi Y, Hirota K. Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells. Cell Mol Immunol. (2024) 21:1183–200. doi: 10.1038/s41423-024-01218-x - DOI - PMC - PubMed
    1. Sachen KL, Hammaker D, Sarabia I, Stoveken B, Hartman J, Leppard KL, et al. . Guselkumab binding to CD64(+) IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling. Front Immunol. (2025) 16:1532852. doi: 10.3389/fimmu.2025.1532852 - DOI - PMC - PubMed
    1. Zhou L, Wang Y, Wan Q, Wu F, Barbon J, Dunstan R, et al. . A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. (2021) 13:1964420. doi: 10.1080/19420862.2021.1964420 - DOI - PMC - PubMed

LinkOut - more resources